We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Formulation Comparison in Normal Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01250197
First Posted: November 30, 2010
Last Update Posted: December 22, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Aerie Pharmaceuticals
November 29, 2010
November 30, 2010
December 22, 2010
November 2010
December 2010   (Final data collection date for primary outcome measure)
Ocular safety [ Time Frame: 3 weeks ]
The primary safety endpoints will be visual acuity, objective biomicroscopic and ophthalmoscopic examination, and subjective comfort as measured by adverse events in response to subject symptom queries.
Same as current
Complete list of historical versions of study NCT01250197 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Formulation Comparison in Normal Volunteers
A Double-masked, Crossover Study Assessing the Ocular and Systemic Safety and Systemic Absorption of Two Formulations of 0.5% AR-12286 Ophthalmic Solution in Normal Volunteers
This is a double-masked, single-center, crossover study in which normal volunteers will be randomized to receive one of two formulations of 0.5% AR-12286 Ophthalmic Solution for 8 days. Subjects will undergo a minimum 7-day washout, and then receive the alternate treatment for 8 days.
Not desired.
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Normal Volunteers
Drug: AR-12286
Ophthalmic Solution
  • Experimental: Formulation A
    AR-12286 Ophthalmic Solution Formulation A
    Intervention: Drug: AR-12286
  • Experimental: Formulation B
    AR-12286 Ophthalmic Solution Formulation B
    Intervention: Drug: AR-12286
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
December 2010
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Normal volunteers

Exclusion Criteria:

  • Active ophthalmic or systemic disease
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01250197
AR-12286-CS101
No
Not Provided
Not Provided
Thomas van Haarlem, M.D., Aerie
Aerie Pharmaceuticals
Not Provided
Study Director: Tom van Haarlem, MD Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP
To Top